<DOC>
	<DOCNO>NCT02371850</DOCNO>
	<brief_summary>This single-dose , Open-label , Non-Randomized , 2-way Crossover Bioequivalence Study compare nicotine release heat brand name ( Nicoderm CQ ) generic ( Aveva skin patch ) nicotine skin patch adult smoker .</brief_summary>
	<brief_title>Transdermal Patch CVD 1000 : The Effect Heat Nicotine Release From Nicotine Patches Adult Smokers</brief_title>
	<detailed_description>This research study intend determine effect heat FDA-approved nicotine transdermal patch whether heat apply result nicotine absorb skin without apply heat . This important give little known release nicotine affect heat , particularly generic product also available counter . This study use nicotine patch ( brand name generic patch ) approve Food Drug Administration ( FDA ) already sell counter customer United States , include placebo .</detailed_description>
	<mesh_term>Nicotine</mesh_term>
	<criteria>1 . Men nonpregnant woman ethnic background age 18 45 year old 2 . Subjects cigarette smoker smoke least 5 cigarette per day one year . 3 . Provide write informed consent initiation study procedure . 4 . Available followup plan duration study 5 . Able communicate well investigator 6 . Able adhere study restriction examination schedule . 7 . Subjects within ideal body weight ( BMI &gt; 17 &lt; = 25 ) 8 . Demonstrate comprehension protocol procedure knowledge study passing ( &gt; 70 % correct response ) write examination contain 20 multiple choice true false question cover aspect study include purpose , procedure , risk benefit . 9 . Subjects deem eligible judge Medically Accountable Investigator ( MAI ) determine medical history , physical examination , medication history . 10 . Have normal blood pressure ( systolic : 90140 mmHg ; diastolic : 5090 mmHg ) heart rate ( 55100 bpm ) , 11 . Have normal screen laboratory WBC , Hgb , platelet , sodium , potassium , chloride , bicarbonate , BUN , creatinine , ALT AST 12 . Have normal screening laboratory urine protein urine glucose . 13 . Female subject must nonchildbearing potential ( define surgically sterile [ i.e . history hysterectomy tubal ligation ] postmenopausal 1 year ) , childbearing potential , must nonpregnant time enrollment morning procedure day , must agree use hormonal barrier birth control implant , injectables , combine oral contraceptive , intrauterine device ( IUDs ) , sexual abstinence , vasectomized partner . 14 . Agrees participate another clinical study study period . 15 . Agrees donate blood blood bank throughout participation study least 3 month last procedure day . 16 . Have normal ECG 17 . Be smoker willing refrain smoking 10 hour prior , , procedure day study . 1 . Subjects nonsmoker smoke less 5 cigarette per day 2 . Women pregnant lactate positive serum pregnancy test enrollment morning procedure day . 3 . Participation ongoing investigational drug trial clinical drug trial 4 . Abnormal Vital sign , define : Hypertension ( systolic blood pressure &gt; 140 mm Hg diastolic blood pressure &gt; 90 mm Hg ) rest 2 separate day ) Heart rate &lt; 55 rest 2 separate day Respiratory rate &gt; 20 5 . Temperature &gt; 38.0 ºC ( 100.4 ºF ) symptom acute selflimited illness upper respiratory infection gastroenteritis within 7 day administration transdermal patch . 6 . Active positive Hepatitis B , C , HIV serologies 7 . Positive urine drug screen test 8 . Use prescription medication period 0 30 day overthe counter medication ( vitamin , herbal supplement birth control medication include ) period 0 5 day entry study 9 . Donation loss great one pint blood within 60 day entry study 10 . Any prior serious adverse reaction hypersensitivity nicotine inactive ingredient patch ( acrylate adhesive , polyester , silicone , ethylene vinyl acetatecopolymer polyisobutylene polyethylene ) 11 . Have diagnosis schizophrenia major psychiatric diagnosis . 12 . Received experimental agent ( vaccine , drug , biologic , device , blood product medication ) within 1 month enrollment study expect receive experimental agent study . 13 . Any condition would , opinion Medically Accountable Investigator ( MAI ) , place subject unacceptable risk injury render subject unable meet requirement protocol . 14 . Inability communicate cooperate investigator 15 . History consumption alcohol within 24 hour prior dose administration 16 . Scarring upper arm , include tattoo plan site patch placement make skin reaction evaluable 17 . Subject currently follow condition : 1 . Thrombophlebitis , thromboembolic disorder 2 . A past history deep vein thrombophlebitis thromboembolic disorder 3 . Cerebrovascular coronary artery disease ( current past history ) 4 . Valvular heart disease complication 5 . Severe hypertension 6 . Diabetes vascular involvement 7 . Headaches focal neurological symptom 8 . Major surgery prolong immobilization 18 . Medical history serious chronic condition ( e.g . allergic condition anaphylaxis , asthma generalize drug reaction ) . 19 . Medical history significant dermatologic disease condition , atopy , psoriasis , vitiligo condition know alter skin appearance physiologic response ( e.g . diabetes , porphyria ) . 20 . History significant dermatologic cancer ( e.g . melanoma , squamous cell carcinoma ) , except basal cell carcinomas superficial involve investigative site . 21 . Within 10 hour prior dose , use nicotine product ( e.g . nicotine gum nicotinecontaining product ) would significantly influence exaggerate response nicotine patch use study . 22 . Within 72 hour prior dose , use antihistamine use topical drug patch site . 23 . Subject obvious difference skin color arm presence skin condition , open sore , scar tissue , tattoo , coloration would interfere placement test article , skin assessment , reaction drug .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>Bioequivalence</keyword>
	<keyword>Therapeutic Equivalency</keyword>
</DOC>